I guess it was just a bit unclear in the blues. I think I understood.
For the last part, in terms of the federal role, my understanding was that you wanted both options looked at, a separate federal stand-alone program as well as the maintenance of existing provincial and territorial programs.
The other thing is that I think the committee agreed we would include all the exemptions from the U.K. as well on the copayment question, zero for generics, $5 for brand name, and then exemptions for seniors, students, pregnant women, etc.
At the beginning the final decision was discussed, but I don't know whether the committee agreed to it.
In terms of procedure, the next steps would be as follows: The chair will send, on behalf of the committee, a letter that I would draft reflecting the decisions made. Once we receive the terms of reference from the PBO, if there were any questions, the PBO could come in and answer them directly.